HK1115032A1 - 通過調節花生四烯酸新陳代謝或信號傳導途徑進行骨治療的方法 - Google Patents

通過調節花生四烯酸新陳代謝或信號傳導途徑進行骨治療的方法

Info

Publication number
HK1115032A1
HK1115032A1 HK08110438.1A HK08110438A HK1115032A1 HK 1115032 A1 HK1115032 A1 HK 1115032A1 HK 08110438 A HK08110438 A HK 08110438A HK 1115032 A1 HK1115032 A1 HK 1115032A1
Authority
HK
Hong Kong
Prior art keywords
modulating
methods
signaling pathway
arachidonic acid
bone treatment
Prior art date
Application number
HK08110438.1A
Other languages
English (en)
Inventor
James Patrick Oconnor
Original Assignee
Accelalox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accelalox Inc filed Critical Accelalox Inc
Publication of HK1115032A1 publication Critical patent/HK1115032A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK08110438.1A 2005-08-18 2008-09-19 通過調節花生四烯酸新陳代謝或信號傳導途徑進行骨治療的方法 HK1115032A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70983805P 2005-08-18 2005-08-18
PCT/US2006/032367 WO2007022427A2 (en) 2005-08-18 2006-08-18 Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway

Publications (1)

Publication Number Publication Date
HK1115032A1 true HK1115032A1 (zh) 2008-11-21

Family

ID=37758443

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08110438.1A HK1115032A1 (zh) 2005-08-18 2008-09-19 通過調節花生四烯酸新陳代謝或信號傳導途徑進行骨治療的方法

Country Status (9)

Country Link
US (3) US7829535B2 (zh)
EP (1) EP1947942B1 (zh)
JP (1) JP2009504776A (zh)
CN (1) CN101277614A (zh)
AU (1) AU2006279325B2 (zh)
CA (1) CA2619608C (zh)
HK (1) HK1115032A1 (zh)
IL (1) IL189553A (zh)
WO (1) WO2007022427A2 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1947942B1 (en) * 2005-08-18 2015-07-29 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8962633B2 (en) * 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
WO2009105723A2 (en) * 2008-02-22 2009-08-27 Accelalox, Inc. Novel methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
EP2285803A4 (en) 2008-05-23 2011-10-05 Amira Pharmaceuticals Inc Inhibitor of 5-Lipoxygenase Activating Protein
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
CN106822080A (zh) 2009-04-29 2017-06-13 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
US20110021560A1 (en) * 2009-06-23 2011-01-27 University Of Massachusetts Medical School Compositions And Methods For Regulating Chondrocyte Proliferation In Bone Disorders
GB0912159D0 (en) * 2009-07-14 2009-08-26 Imp Innovations Ltd Methods
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
US20140056960A1 (en) * 2010-12-29 2014-02-27 Imperial Innovations Limited Methods for Improving Fracture Healing and Bone Formation
US10130654B2 (en) * 2011-05-24 2018-11-20 Hangli Biosciences Co., Ltd. Method of inducing osteogensis and promoting osseointegration around an implant
US20120316111A1 (en) * 2011-06-08 2012-12-13 Southwest Research Institute BMP-2 Upregulating Compounds For Healing Bone Tissue And Screening Methods For Selecting Such Compounds
US9216181B2 (en) 2011-06-08 2015-12-22 Southwest Research Institute BMP-2 upregulating compounds for healing bone tissue and screening methods for selecting such compounds
KR101332074B1 (ko) 2011-07-14 2013-11-22 숙명여자대학교산학협력단 에스큘레틴을 유효성분으로 함유하는 골 손실 억제용 조성물
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
EP2865756A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
ES2878405T3 (es) * 2014-02-04 2021-11-18 Bioscience Pharma Partners Llc Uso de inhibidores de flap para reducir la lesión mediada por neuroinflamación en el sistema nervioso central
CN105327333B (zh) * 2015-10-30 2018-09-07 大连大学 可促进牙种植体周围成骨的口腔施用组合物及其制剂
US10806942B2 (en) 2016-11-10 2020-10-20 Qoravita LLC System and method for applying a low frequency magnetic field to biological tissues
EP3965882A4 (en) 2019-05-06 2023-01-18 Kamran Ansari THERAPEUTIC ARRAYS OF PLANAR COILS DESIGNED TO GENERATE PULSED ELECTROMAGNETIC FIELDS AND EMBEDDED IN CLOTHING
US11020603B2 (en) 2019-05-06 2021-06-01 Kamran Ansari Systems and methods of modulating electrical impulses in an animal brain using arrays of planar coils configured to generate pulsed electromagnetic fields and integrated into clothing
CN110438096A (zh) * 2019-08-12 2019-11-12 江苏省农业科学院 修饰脂肪氧合酶二级结构以降低其ɑ-螺旋和β-折叠含量的方法及其在食品行业的用途
CA3170698A1 (en) * 2020-09-21 2022-03-24 Reveragen Biopharma, Inc. Vamorolone for the treatment of muscular dystrophy
WO2022251254A1 (en) * 2021-05-24 2022-12-01 The Johns Hopkins University Pharmacological intervention of the arachidonic acid pathway to cure amyotrophic lateral sclerosis
CN118159337A (zh) * 2021-10-13 2024-06-07 通用电气精准医疗有限责任公司 使用神经调节对晚期反应基因的激活
CN116139159A (zh) * 2022-10-27 2023-05-23 南开大学 一种prdx6蛋白的抑制剂在制备改善氧化应激损伤的药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649673B2 (en) 1990-04-30 1994-06-02 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of arachidonic acid metabolism
US5534524A (en) * 1994-05-09 1996-07-09 Board Of Regents, The University Of Texas System Suppression of bone resorption by quinolines
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
CA2224563A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
CA2278190A1 (en) 1997-02-04 1998-08-06 Hong-Suk Suh 3-amino-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
US6242012B1 (en) * 1999-10-19 2001-06-05 Thomas Newmark Herbal composition for promoting hormonal balance in women and methods of using same
WO2001041753A2 (en) 1999-12-07 2001-06-14 Rutgers, The State University Of New Jersey Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds
NZ531226A (en) 2001-08-30 2006-07-28 Merckle Gmbh Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration
KR100789567B1 (ko) 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
CN1287789C (zh) 2002-02-08 2006-12-06 霍夫曼-拉罗奇有限公司 15－脂肪氧化酶抑制剂在制备减少骨损失的药物中的应用
US7108868B2 (en) * 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
JP4503436B2 (ja) * 2002-07-08 2010-07-14 ファイザー・プロダクツ・インク 糖質コルチコイド受容体のモジュレーター
DK1587506T3 (da) * 2002-12-18 2008-11-24 Algorx Administration af capsaicinoider
US7256211B1 (en) 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
EP1643961A4 (en) * 2003-07-01 2007-09-12 Microbia Inc COX -2 INHIBITORS AND FAAH
WO2005123130A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
EP1947942B1 (en) * 2005-08-18 2015-07-29 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
WO2009105723A2 (en) 2008-02-22 2009-08-27 Accelalox, Inc. Novel methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway

Also Published As

Publication number Publication date
US20110124717A1 (en) 2011-05-26
WO2007022427A2 (en) 2007-02-22
US20150320697A1 (en) 2015-11-12
US7829535B2 (en) 2010-11-09
CA2619608A1 (en) 2007-02-22
CA2619608C (en) 2016-02-02
WO2007022427A9 (en) 2007-10-18
IL189553A0 (en) 2008-08-07
US8980851B2 (en) 2015-03-17
EP1947942B1 (en) 2015-07-29
EP1947942A2 (en) 2008-07-30
WO2007022427A3 (en) 2007-08-30
JP2009504776A (ja) 2009-02-05
AU2006279325B2 (en) 2013-06-27
EP1947942A4 (en) 2010-04-14
IL189553A (en) 2013-05-30
US20080280826A1 (en) 2008-11-13
CN101277614A (zh) 2008-10-01
AU2006279325A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
IL189553A0 (en) Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
HK1216602A1 (zh) 骨胳治療系統及方法
EP2110799A4 (en) SIMULATION SYSTEM FOR TRAINING IN ARTHROSCOPIC SURGERY
IL197001A0 (en) Combination treatment for metabolic disorders
ZA200709257B (en) Bone fixation apparatus
GB0511847D0 (en) Medical apparatus
EP2252224A4 (en) BONE FIXING SYSTEM
EP2367489A4 (en) CERCLAGE SYSTEM FOR BONE
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
GB2465156B (en) Bone fixation system
EP2022433A4 (en) ENDOSCOPE TREATMENT SYSTEM
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP1958648A4 (en) THERAPEUTIC PROCESS FOR BLOOD CLEANING DISORDER
HK1119577A1 (en) Compounds for the treatment of metabolic disorders
ZA200808963B (en) Compounds for the treatment of metabolic disorders
EP1855729A4 (en) sterilization
IL198166A0 (en) Electrolytic tissue treatment devices
HK1132458A1 (en) Ophthalmic composition containing alginic acid or salt thereof
EP2067131A4 (en) MEDICAL EDUCATION SYSTEM
EP2116203A4 (en) BAND FOR BONE FIXING
IL192852A0 (en) Compounds for the treatment of metabolic disorders
EP2242436A4 (en) DEVICE FOR BONE FIXING
FR2937531B1 (fr) Systeme d'osteosynthese rachidienne
EP1858841A4 (en) STERILIZING COMPOSITION CONTAINING W-ALKOXYPEROXY CARBOXYLIC ACID
IL192851A0 (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190816